Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial
EndocrinologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Journal of the American Society of Nephrology : JASN
- Publicado em
- 6 nov 2025
- Citações
- 5
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial
Amy K Mottl, Charlie Scott, Jennifer B Green, Hiddo J.L. Heerspink, Johannes F E Mann, Janet B McGill, Masaomi Nangaku, Julio Rosenstock, Peter R Rossing, Li Li et al.
Descritores MeSH
- Sodium-Glucose Transporter 2 Inhibitors
- Benzhydryl Compounds
- Creatinine
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Glucosides
- Naphthyridines
- Renal Insufficiency, Chronic
- Albuminuria
- Aged
Veja também
Estudos relacionados
- Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
- COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics
- Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant-Level Exploratory Analysis of the Randomised CONFIDENCE Trial
- Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses